Drug intelligence / Profile preview

hemay102

Development stage: Phase 1
Lead developer: Tianjin Hemay Biotech
Modality: Small Molecules
Administration: Intravenous

Overview

Hemay102 is a small molecule, cytotoxic anticancer agent classified as an anthraquinone tetracycline derivative. It exerts its antitumor effects primarily by inhibiting the activity of topoisomerase II (TopoII), an enzyme critical for DNA replication and cell division. This mechanism disrupts DNA processes in rapidly dividing tumor cells, leading to cell death. The drug was developed by Tianjin Hemay Pharmaceutical and related entities for the treatment of solid tumors, with a particular focus on hepatocellular carcinoma (liver cancer). Clinical development reached Phase I trials in China but has since been suspended[1][2][5][8].

Other names: HEMAY 102HEMAY102HEMAY-102

Targets

TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on hemay102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hemay102.

Explore the full profile